Independent Financial Group LLC Takes Position in Novartis AG $NVS

Independent Financial Group LLC acquired a new position in Novartis AG (NYSE:NVS) during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund acquired 4,205 shares of the company’s stock, valued at approximately $642,000.

Several other large investors have also made changes to their positions in the business. Arlington Trust Co LLC bought a new position in Novartis in the 4th quarter worth approximately $25,000. Archer Investment Corp boosted its position in shares of Novartis by 93.0% in the first quarter. Archer Investment Corp now owns 166 shares of the company’s stock valued at $25,000 after acquiring an additional 80 shares during the period. CrossGen Wealth LLC bought a new stake in shares of Novartis in the fourth quarter valued at approximately $28,000. Bank of Jackson Hole Trust grew its stake in shares of Novartis by 425.0% in the fourth quarter. Bank of Jackson Hole Trust now owns 231 shares of the company’s stock worth $32,000 after acquiring an additional 187 shares during the last quarter. Finally, Measured Wealth Private Client Group LLC bought a new position in Novartis during the third quarter worth $33,000. Institutional investors and hedge funds own 13.12% of the company’s stock.

Novartis News Summary

Here are the key news stories impacting Novartis this week:

• Positive Sentiment: Novartis beat Q2 estimates, reporting EPS of $2.41 versus $2.20 expected and revenue of $14.41 billion versus $14.07 billion expected, driven by strong sales in key brands and lower costs. Article Title
• Positive Sentiment: Management reaffirmed full-year 2026 guidance, which suggests the company is still confident that growth from newer drugs can outweigh declines in older products. Article Title
• Positive Sentiment: Several articles also pointed to a more constructive investor view, including a Seeking Alpha “buy thesis” upgrade and commentary that Novartis returned to sales growth as newer medicines offset generic pressure. Article Title
• Neutral Sentiment: CEO Vas Narasimhan said there is “no change of plans,” with key clinical trial readouts expected in the second half of the year. That keeps the pipeline story in focus, but it is still a waiting game. Article Title
• Negative Sentiment: Investors are still watching for headwinds from generic competition and steep sales declines in Entresto, which could limit how quickly Novartis can sustain growth. Article Title

Wall Street Analyst Weigh In

Several research firms recently weighed in on NVS. Weiss Ratings cut shares of Novartis from a “buy (a-)” rating to a “buy (b)” rating in a research note on Wednesday, April 29th. Citigroup restated a “buy” rating on shares of Novartis in a research note on Wednesday. Finally, Morgan Stanley upped their price target on Novartis from $143.00 to $170.00 and gave the company an “overweight” rating in a report on Thursday, March 26th. Seven research analysts have rated the stock with a Buy rating, seven have issued a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $141.20.

Novartis Stock Performance

NYSE:NVS opened at $153.04 on Thursday. The firm has a market capitalization of $292.02 billion, a PE ratio of 23.08, a price-to-earnings-growth ratio of 2.66 and a beta of 0.45. The company has a quick ratio of 0.65, a current ratio of 0.85 and a debt-to-equity ratio of 0.96. Novartis AG has a 12-month low of $112.34 and a 12-month high of $170.46. The firm has a 50-day moving average price of $151.68 and a 200 day moving average price of $151.99.

Novartis (NYSE:NVS) last released its quarterly earnings data on Tuesday, June 30th. The company reported $2.41 earnings per share for the quarter. Novartis had a return on equity of 38.23% and a net margin of 23.29%.The company had revenue of $14.95 billion for the quarter. Research analysts anticipate that Novartis AG will post 8.75 earnings per share for the current fiscal year.

About Novartis

Novartis is a Swiss multinational pharmaceutical company headquartered in Basel that researches, develops, manufactures and commercializes prescription medicines and related health-care products. Formed through the 1996 merger of Ciba-Geigy and Sandoz, Novartis operates globally and focuses on bringing therapeutics from discovery through clinical development to commercial markets worldwide.

The company’s activities center on innovative pharmaceuticals across several therapeutic areas, including oncology, immunology, cardiovascular and metabolic diseases, neuroscience and ophthalmology, alongside capabilities in advanced therapies such as biologics, cell and gene therapies.